Recent News

• 09.04.2025 - Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
• 09.04.2025 - Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
• 08.20.2025 - Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
• 08.20.2025 - Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
• 08.13.2025 - Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
• 08.13.2025 - Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
• 08.05.2025 - Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
• 08.05.2025 - Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

Recent Filings

• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 8-K Current report
• 08.05.2025 - EX-99.1 EX-99.1
• 06.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2025 - 4 Statement of changes in beneficial ownership of securities